DOCSLIB.ORG

Issue Brief. Gene Therapy in 2019: Milestones and Challenges

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Issue Brief. Gene Therapy in 2019: Milestones and Challenges PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE WWW.PCORI.ORG | [email protected] | FOLLOW US @PCORI 1828 L STREET NW, SUITE 900 | WASHINGTON, DC 20036 | 202.827.7700 ISSUE BRIEF Gene Therapy in 2019: Milestones and Challenges or as long as medical researchers have been able to identify the genes responsible for particular KEY POINTS Fdiseases, they have set their sights on using that knowledge to devise gene therapies—ways to repair or Gene therapy research has yielded 10 circumvent the abnormal gene expression—to prevent approved treatments so far, and dozens or treat those diseases. What is the state of the science more are on the horizon. These therapies of gene therapy in 2019? What can we expect in the target both rare genetic diseases and more near future? And what gaps and challenges stand in the common diseases like some cancers. way of realizing our goals? Both research and clinical care face To address those questions, we reviewed the findings technological, ethical, and especially from completed trials of gene therapies and those financial challenges. ongoing trials that have completed recruitment. We also interviewed a diverse group of stakeholders, including Experts and stakeholders are exploring clinicians, pharmaceutical industry representatives, ways to tackle some of the most patients and patient advocates, government and private challenging issues, such as modifying insurers, and policy makers on the challenges and the approval process and how to pay important issues as well as their hopes for gene therapy. for treatment. This brief summarizes the findings of the report for policy makers. Gene Therapy Explained administered to patients directly (to modify cells in the body) or they may be transferred to a patient’s cells in the We define gene therapies as products that replace or lab with the modified cells then being transferred back to circumvent defective genes by a variety of mechanisms: the patient. Since 2013, 10 therapies have successfully navigated f Replacing a disease-causing gene with a healthy the multi-phase Food and Drug Administration (FDA) copy of the gene, approval process, for the treatment of 11 different f Repairing, inactivating, or modulating a disease- diseases (Table 1). Only a few of the therapies are causing gene that is not functioning properly, or expected to cure the targeted disease with one f Introducing a new or modified gene into the treatment, while most other therapies require body to help treat a disease repeated—possibly lifelong—treatments. However, whether or not potentially curative treatments live up to Gene therapy products that replace defective genes that potential has yet to be seen. Treated patients have or introduce new genes comprise the gene itself and not yet been followed long enough to see if benefits a vector (delivery vehicle) that consists of a tiny piece persist, compared to the 10 or more years needed to see of viral or bacterial DNA. These products may be if cures have been realized and harms are avoided. RESEARCH DONE DIFFERENTLY® Table 1. Approved Gene Therapies as of 2019 Treatment Repeated Treatment Disease Mechanism of Gene Therapy (Generic names, Year approved) Required? Metabolic and Other Multi-Organ Diseases Homozygous familial Kynamro Antisense Yes hypercholesterolemia (Mipomersen sodium, 2013) Vision and Neuromuscular Diseases Biallelic RPE65 mutation- Luxturna Adeno-associated viral vector No associated retinal dystrophy (Voretigene neparvovec, 2017) serotype 2 (AAV2) Duchenne muscular dystrophy Eteplirsen Antisense Yes (Exondys 51, 2016) Spinal muscular atrophy Spinraza Antisense Yes (Nusinersen, 2016) Polyneuropathy of hereditary Tegsedi Antisense Yes transthyretin amyloidosis (Inotersen, 2018) Hereditary transthyretin Patisiran RNA interference (RNAi) Yes amyloidosis with (Onpattro, ALN-TTR02, 2018) polyneuropathy Spinal muscular atrophy Zolgensma1 Adeno-associated virus (AAV 9) No (Onasemnogene abeparvovec-xioi, 2019) Cancer Melanoma (inoperable lesions Imlygic Genetically modified oncolytic Yes such as those in organs) (Talimogene laherparepvec, 2015) viral therapy–replication- competent, attenuated derivative of herpes simplex virus type 1 Relapsed or refractory large Yescarta Chimeric antigen receptor No B-cell lymphoma (Axicabtagene ciloleucel, 2017) (CAR)-T CD19-targeted cell immunotherapy Adult relapsed or refractory Kymriah Chimeric antigen receptor No large B-cell lymphoma (Tisagenlecleucel, 2018) (CAR)-T CD19-targeted cell immunotherapy Pediatric refractory B-cell Kymriah Chimeric antigen receptor No precursor acute lymphoblastic (Tisagenlecleucel, 2017) (CAR)-T CD19-targeted cell leukemia immunotherapy 1 Zolgensma was approved by the FDA after completion of the report on which this brief is based. 2 Issue Brief The approval process was designed to ensure, to the “cure” that has been a prime goal of gene therapy), and it extent possible, that a medical intervention is effective, has the potential to cause severe liver damage. that all potential safety issues are considered, and that Another gene therapy, LuxturnaTM (Voretigene the benefit-to-risk ratio is acceptable. Gene therapy neparvovec), approved in 2017 for the treatment of a interventions may also be subject to ethical and social rare eye disease, was the first approved to make use of scrutiny, as well, to gain approval. a—theoretically—benign viral vector to transport genetic Our review identified dozens of seemingly promising material into human cells. Localized side effects are therapies that have undergone testing in controlled trials, observed in about two-thirds of recipients. although at least one treatment has been approved Gene therapies have also been approved for five without a placebo-controlled trial, because such trials neuromuscular disorders. While SpinrazaTM (nusinersen) are not always feasible for gene therapies targeted to has been approved to treat a rare condition called extremely rare or devastating diseases. And even though spinal muscular atrophy with repeated administration, some gene therapies appear promising and have been ZolgensmaTM (Onasemnogene abeparvovec-xioi) has approved or are near approval, the evidence to support just been approved to treat this condition with a single clear clinical effectiveness may be lacking. administration, which may cost over $2 million. Conditions for which Gene Therapies Though much of the initial promise of gene therapies lay in their potential to treat rare, incurable conditions, Have Been Approved science is discovering that these therapies can The interventions approved by the FDA thus far target successfully treat much more common diseases such as a variety of diseases, ranging from metabolic disorders cancer and blood disorders. to neuromuscular disorders to cancer. The first gene therapy to be approved, KynamroTM (Mipomersen sodium), Therapies on the Horizon treats familial (inherited) hypercholesterolemia; this More than 75 additional gene therapies have shown condition results in significant suffering and decreases life promise in clinical trials and may be close to approval to expectancy by causing dangerously high blood cholesterol treat patients. These therapies are being tested for their levels. The disease can be caused by a variety of defects in ability to treat multiple disease types, from the exceedingly any of several genes that encode the proteins involved in rare (like cerebral adrenoleukodystrophy, commonly forming and transporting cholesterol throughout the body. known as Lorenzo’s Oil disease) to the far more common The approved therapy appears to work in many but diseases like mesothelioma and Parkinson’s (a sample of not all patients, highlighting the vital importance of conditions is shown in Table 2). As Table 2 shows, some knowing the precise genetic cause of a patient’s disease. diseases are the targets of multiple therapeutic efforts, In addition, this treatment must be administered via partly because of the many different mutations that can repeated injection (contrary to the single-treatment have the same clinical presentation. Table 2. Examples of Diseases for which Gene Therapies Are in Clinical Trials (Number of Unique Therapies) Metabolic and Other Multi-Organ Diseases Cancer f Amyloidoses (5) f Adult solid tumors (16) f Familial amyloidotic neuropathies (1) f Pediatric neuroblastoma (1) f Cerebral adrenoleukodystrophy or Lorenzo’s Oil f Leukemia and lymphoma (20) disease (1) f Mucopolysaccharidosis I, II, IIIa, b (1) Immune Disorders Vision Diseases f HIV (2) f X-linked retinitis pigmentosa (2) Blood Diseases Neuromuscular Diseases f Hemophilia A and B (5) f Alzheimer’s disease (1) f Huntington’s disease (1) f Limb-Girdle muscular dystrophy, type 2B, 2D, 2E (4) Gene Therapy in 2019: Milestones and Challenges 3 Realizing the Promise of Gene Therapy: PAYMENT Challenges and Opportunities One of the greatest challenges may be how to pay for treatment—both for single-administration therapies with The potential promise gene therapy holds for treating a large upfront costs and for those that require repeated, broad variety of heretofore untreatable diseases must be often lifelong, administration—and how equitable access tempered by the many challenges moving forward. We to treatment will be assured. Prices can range from present here some of the unknowns for which answers the thousands to the millions and per person lifetime will be most useful for policy makers. costs for some approved therapies can reach well over $1 million, with the prevalence of the conditions varying LONG-TERM
Load more

Recommended publications
  • Spotlight on Market Access Actionable Understandings from AIS Health’S In-Depth Coverage
    Spotlight on Market Access Actionable understandings from AIS Health’s in-depth coverage September 16, 2019 Recent Situations Stress That Data Is More Important Than Ever to FDA, Drug Uptake 2 Clinical Trials by Indication: Q2 2019 A pair of drugmakers and the FDA found themselves in the news lately, but it’s safe to say it wasn’t for the reasons they would prefer. Both situations Reality Check: PCSK9 Inhibitors 8 stress the importance of data needed to secure product approvals, and, per- haps, payer and provider uptake. On Aug. 6, the FDA put out a statement addressing “data accuracy issues” with Zolgensma (onasemnogene abeparvovec-xioi), a new gene ther- apy to treat spinal muscular atrophy in people less than 2 years old who have bi-allelic mutations in the survival motor neuron 1 gene, including those who are presymptomatic when diagnosed. The one-time therapy has the distinction of being the most expensive drug in the world, with a price tag of $2.1 million. The FDA approved the drug from AveXis, Inc. on May 24 (SMA 7/1/19, p. 6). On June 28, AveXis — which was acquired by Novartis AG last year — notified the agency that there was “a data manipulation issue that impacts the accuracy of certain data from product testing performed in animals sub- mitted in the biologics license application (BLA) and reviewed by the FDA.” continued on p. 3 Report Reveals That Almost 100 RM/AT Products Are in Phase III Clinical Trials This past quarter saw two new gene therapies: Novartis AG subsidiary AveXis, Inc.’s Zolgensma (onasemnogene abeparvovec-xioi) received FDA approval May 24 for the treatment of spinal muscular atrophy (SMA 7/1/19, p.
    [Show full text]
  • Curriculum Vitae
    Curriculum Vitae PERSONAL INFORMATION Ulrike Schara WORK EXPERIENCE 1991- 1997 Education in Paediatrics Paediatric Outpatient Centre,City Hospital Gelsenkirchen. (Germany) Paediatric Outpatient Centre. City Hospital Gelsenkirchen.<br/>Childrens Hospital, Ruhr University Bochum<br/> 1998- 2002 Senior Neuropediatrics Children&apos;s University Hospital Bochum (Germany) . 2002- 2003 Head of Neuropediatrics Children&apos;s University Hospital Bochum (Germany) 2004- 2006 Head of Neuropediatrics Children&apos;s Hospital, City of Neuss (Germany) 2007- Present Head of the Neuropaediatric Outpatient Centre and Consultant for Neuropaediatrics University of Essen (Germany) EDUCATION AND TRAINING 1991- 2012 MD, Professor Ruhr University of Bochum, Germany University of Essen (Germany) ADDITIONAL INFORMATION Expertise Publications Publcations of the past 5 years 1.Rudnik-Schöneborn S, Tölle D, Senderek J, Eggermann K, Elbracht M, Kornak U, von der Hagen M, Kirschner J, Leube B, Müller-Felber W, Schara U, von Au K, Wieczorek D, Bußmann C, Zerres K. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. Clin Genet. 2016 Jan;89(1):34-43 2.Byrne S, Jansen L, U-King-Im JM, Siddiqui A, Lidov HG, Bodi I, Smith L, Mein R, Cullup T, Dionisi-Vici C, Al-Gazali L, Al-Owain M, Bruwer Z, Al Thihli K, El-Garhy R, Flanigan KM, Manickam K, Zmuda E, Banks W, Gershoni-Baruch R, Mandel H, Dagan E, Raas-Rothschild A, Barash H, Filloux F, Creel D, Harris M, Hamosh A, Kölker S, Ebrahimi-Fakhari D, Hoffmann GF, Manchester D, Boyer PJ, Manzur AY, Lourenco CM, Pilz DT, Kamath A, Prabhakar P, Rao VK, Rogers RC, Ryan MM, Brown NJ, McLean CA, Said E, Schara U, Stein A, Sewry C, Travan L, Wijburg FA, Zenker M, Mohammed S, Fanto M, Gautel M, Jungbluth H.
    [Show full text]
  • Immunoprophylaxis of Influenza Using AAV Vector Delivery of Cross
    Immunoprophylaxis of Influenza using AAV Vector Delivery of Cross-Subtype Neutralizing Single Domain Antibodies JOANNE MARIE M. DEL ROSARIO Thesis submitted for the degree of Doctor of Philosophy Infection and Immunity University College London 2020 To Chris, as fate would have it. To Teki, thank you for everything. 2 DECLARATION I, Joanne Marie M. Del Rosario, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. __________________________ 3 ABSTRACT Cross-subtype neutralizing single domain antibodies against influenza present new opportunities for immunoprophylaxis and pandemic preparedness. Their simple modular structure and single open reading frame format are highly amenable to gene therapy-mediated delivery. R1a-B6, an alpaca-derived single domain antibody (nanobody), that is capable of potent cross-subtype neutralization in vitro of H1N1, H5N1, H2N2, and H9N2 influenza viruses, through binding to a highly conserved epitope in the influenza hemagglutinin stem region, was previously described. To evaluate the potential of R1a-B6 for immunoprophylaxis via adeno-associated viral (AAV) vector delivery, it was reformatted as Fc fusions of mouse IgG1 (ADCC-) and IgG2a (ADCC+) isotypes. This is also to extend R1a-B6’s half-life and to assess the requirement for ADCC for efficacy of R1a-B6 in vitro and in vivo. It was found that reformatted R1a-B6 of either mouse IgG isotype retained its potent binding and neutralization activity against different Group I influenza A subtypes in vitro. The findings in this study also demonstrate that a single intramuscular injection in mice of AAV encoding R1a-B6-Fc was able to drive sustained high-level expression (0.5–1.1 mg/mL) of the nanobody-Fc in sera with no evidence of reduction for up to 6 months.
    [Show full text]
  • Innovationsreport 2020 Kurzfassung
    Innovationsreport 2020 Auswertungsergebnisse von Routinedaten der Techniker Krankenkasse aus den Jahren 2017 bis 2018 Herausgeber: Gerd Glaeske Erstellt mit freundlicher Unterstützung der Techniker Krankenkasse (TK) 3 Herausgeber Prof. Dr. Gerd Glaeske Experten für ausgewählte Kapitel Prof. Dr. med. Janbernd Kirschner, Bonn Prof. Dr. med. Dieter Ukena, Bremen Prof. Dr. med. Barbara Schmalfeldt, Hamburg Prof. Dr. med. Wolfgang Schramm, München Autoren Prof. Dr. med. Karl Broich, Dr. Stanislava Dicheva‐Radev, Dörte Fuchs, Prof. Dr. Gerd Glaeske, Dr. Marion Haberkamp, Dr. Iris Hinneburg, Friederike Höfel, Prof. Dr. Janbernd Kirschner, Dr. Wiebke Löbker, Anja Lübs, Dr. André S. Morawetz, Lutz Muth, Dr. Frauke Naumann‐Winter, Linda Richter, Saskia Ritter, Dr. Kristin Sauer, Dr. Birgit Schindler unter Mitarbeit von Esra Aksoy, Friederike Höfel, Berit Marquardt, Linda Richter, Marle Wilhelm Anschrift: Universität Bremen, SOCIUM, Mary‐Somerville‐Str. 5, 28359 Bremen Aus Gründen der besseren Lesbarkeit wurde auf die Nennung beider geschlechtsspezifischer Formen verzichtet. Im Allgemeinen ist aber das jeweils andere Geschlecht ebenfalls gemeint. 2 Glossar .......................................................................................... 7 Vorwort zum Innovationsreport 2020 ...........................................15 Vorwort des Herausgebers ............................................................17 1 Einleitung ................................................................................19 2 Ziele und Methodik..................................................................33
    [Show full text]
  • Zolgensma, INN-Onasemnogene Abeparvovec
    26 March 2020 EMA/200482/2020 Committee for Medicinal Products for Human Use (CHMP) Committee for Advanced Therapies (CAT) Assessment report Zolgensma International non-proprietary name: onasemnogene abeparvovec Procedure No. EMEA/H/C/004750/0000 Note The CAT Assessment report has been endorsed by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 10 2.1. Problem statement ............................................................................................. 10 2.1.1. Disease or condition ......................................................................................... 10 2.1.2. Epidemiology .................................................................................................. 11 2.1.3.
    [Show full text]
  • Med Pharm PA List to Build Pdfs.Xlsx
    The following medications, typically administered in a provider's office or ambulatory/outpatient infusion center, require authorization prior to utilization. Authorization requests can be submitted via the Portal. Additionally, you are welcome to call our member services line to initiate the Prior Authorization process. This list is updated quaterly. Effective date: 1/1/2021 Therapeutic category Brand Name Generic Name HCPCS Immunologic agent Orencia, IV infusion abatacept J0129 Botulinum toxins Dysport abobotulinumtoxin B J0586 HER-2 receptor drug Kadcyla ado-trastuzumab emtansine J9354 Ophthalmic injectable Eylea afilbercept J0178 Enzyme replacement drug Fabrazyme agalsidase beta J0180 Multiple sclerosis drug Lemtrada alemtuzumab J0202 Enzyme replacement drug Lumizyme alglucosidase alfa J0221 Enzyme replacement drug Strensiq asfotase alfa J3590 (non-specific) PD1-PDL1 drug Tecentriq atezolizumab J9022 PD1-PDL1 drug Bavencio avelumab J9023 CAR-T Therapy Yescarta axicabtageneciloleucel inpatient admin Systemic lupus erythematosus (SLE) drug Benlysta belimumab J0490 Antineoplastic agent Beleodaq belinostat J9032 Antineoplastic Belrapzo bendamustine HCl J9036 Antineoplastic Bendeka bendamustine HCl J9034 Antineoplastic agent Treanda bendamustine HCl J9033 Respiratory injectable Fasenra benralizumab J0517 J9035/J3590 (ophthalmology Antineoplastic Avastin bevacizumab uses this non-specific code) Antineoplastic agent Mvasi bevacizumab-awwb Q5107 Antineoplastic agent Zirabev bevacizumab-bvzr Q5118 Antineoplastic agent Blincyto blinatumomab
    [Show full text]
  • Virtual Posters
    VIRTUAL POSTERS Poster # Title Primary Author First Name Primary Author Last Name City State Brain Tumors/OnCology 200 Clinical and Molecular Features of Atypical Pediatric Neurocytoma: A Case Series Adam Kalawi San Diego CA 201 Atypical molecular features of pediatric tectal glioma: A single institutional series Maayan Yakir San Diego CA 202 Hypercalcemia in Use of the Ketogenic Diet for Treatment of Spinal Lipoma Lila Worden Hartford CT Cognitive/Behavioral Disorders (inCluding Autism) 203 The neurodevelopmental profile of HIVEP2-related disorder Alisa Mo Boston MA 204 Burden of disease in a rare neurologic disorder: caregiver’s perspective on Aicardi Goutières Syndrome Francesco Gavazzi Philadelphia PA 205 Diagnosis delay in Aicardi Goutières Syndrome: a parents’ perspective Francesco Gavazzi Philadelphia PA 206 Validation of the telemedicine application of the Gross Motor Function Measure-88 Francesco Gavazzi Philadelphia PA 207 Altered Cerebellar White Matter in Sensory Processing Dysfunction Is Associated With Impaired Multisensory Integration and Attention Elysa Marco San Rafael CA 208 A comparison of the adaptive and autistic behavior in three developmental epileptic encephalopathies – SLC6A1, SCN2A, STXBP1 Kimberly Goodspeed Dallas TX 209 Spatial topography of cross-frequency coupling during NREM sleep is disrupted in Rett Syndrome Patrick Davis Boston MA 210 Serotonin transporter genotype predicts adaptive behavior outcomes in children with autism Kevin Shapiro Los Angeles CA 211 Clinical and Numerical presentation of Neurocognitive
    [Show full text]
  • Pharmacotherapy of Spinal Muscular Atrophy (SMA), 5.01.574
    PHARMACY / MEDICAL POLICY – 5.01.574 Pharmacotherapy of Spinal Muscular Atrophy (SMA) Effective Date: Nov. 1, 2020 RELATED MEDICAL POLICIES: Last Revised: Jan. 31, 2021 None Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Spinal muscular atrophy (SMA) is a rare disease that leads to muscle weakness and atrophy. SMA affects the muscles of the limbs and trunk. SMA is caused by changes to the survival motor neuron 1 gene (SMN1). This gene creates a protein called the survival motor neuron (SMN) protein. Too little of the SMN protein leads to muscle weakness that gets worse over time and muscles that waste away (atrophy). There are different types of SMA. Type 1 SMA, also known as Werdnig-Hoffman disease or infantile SMA, is the most severe form. Symptoms usually start before 6 months of age. The chance of survival to one year of age is 50 percent. Less severe forms are Type 2, also known as Dubowitz disease, and Type 3, or Kugelberg-Welander disease. Evrysdi™ (risdiplam), Spinraza® (nusinersen), and Zolgensma® (onasemnogene abeparvovec- xioi) are three treatments the Food and Drug Administration has approved for SMA. This policy discusses when the use of Evrysdi™, Spinraza®, and Zolgensma® may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals.
    [Show full text]
  • Aetna PA Info
    Procedures, programs and drugs that require precertification Participating provider precertification list Starting June 1, 2021 Applies to the following plans (also see General information section #1-#4, #9-#10): Aetna® plans, except Traditional Choice® plans All health benefits and insurance plans offered and/or underwritten by Innovation Health plans, Inc., and Innovation Health Insurance Company, except indemnity plans, Foreign Service Benefit Plan, MHBP and Rural Carrier Benefit Plan All health benefits and health insurance plans offered, underwritten and/or administered by the following: Banner Health and Aetna Health Insurance Company and/or Banner Health and Aetna Health Plan Inc. (Banner|Aetna), Texas Health +Aetna Health Insurance Company and/or Texas Health+Aetna Health Plan Inc. (Texas Health Aetna), Allina Health and Aetna Health Insurance Company (Allina Health| Aetna), Sutter Health and Aetna Administrative Services LLC (Sutter Health | Aetna) Aetna.com 23.03.882.1 R (6/21) For more information, read all general precertification guidelines Providers may submit most precertification requests electronically through the secure provider website or using your Electronic Medical Record (EMR) system portal. (See #1 in the General Information section for more information on precertification.) Services that require precertification: 1. Inpatient confinements (except hospice) 18. Nonparticipating freestanding ambulatory For example, surgical and nonsurgical stays, surgical facility services, when referred by stays in a skilled nursing facility or rehabilitation a participating provider facility, and maternity and newborn stays that 19. Orthognathic surgery procedures, bone exceed the standard length of stay (LOS). (See grafts, osteotomies and surgical #6 in the General Information section.) management of the temporomandibular 2. Ambulance joint Precertification required for transportation by 20.
    [Show full text]
  • Pre-Certification Requirements for Procedures, Programs & Drugs
    Procedures, programs and drugs that require precertification Participating provider precertification list Starting August 1, 2020 Applies to the following plans (also see General information section #1-#4, #9-#10): Aetna® plans, except Traditional Choice® plans All health benefits and insurance plans offered and/or underwritten by Innovation Health plans, Inc., and Innovation Health Insurance Company, except indemnity plans, Foreign Service Benefit Plan, MHBP and Rural Carrier Benefit Plan All health benefits and health insurance plans offered, underwritten and/or administered by the following: Banner Health and Aetna Health Insurance Company and/or Banner Health and Aetna Health Plan Inc. (Banner|Aetna), Texas Health +Aetna Health Insurance Company and/or Texas Health+Aetna Health Plan Inc. (Texas Health Aetna), Allina Health and Aetna Health Insurance Company (Allina Health| Aetna), Sutter Health and Aetna Administrative Services LLC (Sutter Health | Aetna) aetna.com 23.03.882.1 I (8/20) Proprietary For additional information, read all general precertification information Providers may submit most precertification requests electronically through the secure provider website or using your Electronic Medical Record (EMR) system portal (See #1 in the General Information section for more information on precertification). Services that require precertification: 1. Inpatient confinements (except hospice) 18. Nonparticipating freestanding ambulatory For example, surgical and nonsurgical stays, surgical facility services, when referred stays in a skilled nursing facility or rehabilitation by a participating provider facility, and maternity and newborn stays that 19. Orthognathic surgery procedures, bone grafts, osteotomies and surgical exceed the standard length of stay (LOS) (See #5 management of the temporomandibular in the General Information section). joint 2.
    [Show full text]
  • MSM CH 1200 Draft 06-29-21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER June 29, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER SUBJECT: MEDICAID SERVICES MANUAL CHANGES CHAPTER 1200 – PRESCRIBED DRUGS BACKGROUND AND EXPLANATION Revisions to Medicaid Services Manual (MSM) Chapter 1200 – Prescribed Drugs are being proposed to reflect recommendations approved on January 28, 2021 by the Drug Use Review (DUR) Board. The proposed changes include: Addition of new prior authorization criteria for Evrysdi® (risdiplam) within the new combined Spinal Muscular Atrophy (SMA) Agents section; addition of new prior authorization criteria for Vyondys 53® (golodirsen) within the new combined Duchenne Muscular Dystrophy (DMD) Agents section; Addition of new prior authorization criteria for Qutenza® (capsaicin); new prior authorization criteria for Fintepla® (fenfluramine) and lastly, technical changes to the Immunomodulator Drugs section to correct grammatical and inaccurate information. Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re-arranging of sections was necessary. These changes are effective July 5, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL OL MTL N/A MSM Chapter 1200 - Prescribed Drugs MSM Chapter 1200 - Prescribed Drugs Manual Section Section Title Background and Explanation of Policy Changes, Clarifications and Updates Appendix A Zolgenma® Revised section title
    [Show full text]
  • Measured Moments
    measured by moments 2019 ANNUAL REPORT OUR PROMISE. Rare diseases, real strides to treat them—this is why we’re here. No matter how uncommon the disorder, the life-limiting effects are a daily reality For those aFFected. When Stu Peltz Founded PTC over 20 years ago, he had this unique insight. That’s why we’re creating life-changing treatments every day. The Family Approach In Our DNA We are not simply there For you With every setback and on the rare disease journey, advance, we continue to push but we are with you, because forward every day because we know that family gets its this is not simply a job to us: strength from one another. it’s a calling. We’re in this together. Rare Resolve for The Science Rare Disease of Progress Our people choose to work here We use data and groundbreaking because they believe in the science in our search for moments that we build— progress—progress in in the labs and in the home. rare-disease treatments, of course, but also in the day-to-day lives of those affected. A Message to Our Shareholders Our exceptional team is well positioned to address whatever comes our way thanks to the progress we have made in past years. Stuart W. Peltz, Ph.D., PTC Therapeutics recently marked its We continue to invest in our clinical Chief Executive Ofcer 22nd anniversary, a proud moment stage programs and pipeline across for the company amid a diffcult our small molecule and gene time for all of us globally.
    [Show full text]